THE--.
Page 12, line 1, after "OF" and before "SUMMARY", insert --THE--.
Page 44, before line 1, insert --WHAT IS CLAIMED IS:--.
Page 64, line 1, after "ABSTRACT", insert --OF THE DISCLOSURE--.

In the Claims:

69. (twice amended) A [first] therapeutic agent being a soluble precipitable material which is [adapted] to be converted into an insoluble and non-digestible precipitate by the action of a non-mammalian enzyme[,] when the [first] therapeutic agent [when] is administered to a living host [having] containing a heterogeneous population of cancer cells, the heterogeneous population of cancer cells including at least a [first] sub-population of cancer cells being the [first] target cancer cells[,] each [having] including a first antigenic receptor, a bispecific reagent when administered to a living host being bound to the target cancer cells, the [first] therapeutic agent [being adapted] to be disposed adjacent to the [first] target cancer cells subsequent to the administration to the living host of a [first] bispecific reagent, the [first] bispecific reagent [having] containing two moieties, a first moiety which is a non-mammalian enzyme moiety being a first enzyme moiety, the [first] bispecific reagent further [having] containing a second moiety including a targeting agent moiety which has a substantial affinity for the first antigenic receptor of the [first] target cancer cells[,] the [first] therapeutic agent [being adapted] to be converted in the extra-cellular fluid of the living host, adjacent to the [first] bispecific reagent, into a soluble and non-digestible precipitate which is [a first] an extra-cellular precipitate by the action of the first enzyme moiety of the [first] bispecific reagent, the [first] bispecific reagent [being] to be bound to the

TYPO's

[first] target cancer cells, the [first] therapeutic agent [selected] being from the group consisting of peptides, including opio-melanins, of carbohydrates including cellulose, chitosan, and chitin, of proteoglycans, of synthetic polymers, and of indoxyl compounds [having] containing molecular positions 1-7, the [first] extra-cellular precipitate having an epitope selected from the group consisting of a first antigenic epitope being an epitope which is an integral [of] part of the structure of the [first] extra-cellular precipitate, a second antigenic epitope, and a neo-antigenic third epitope, the neo-antigenic third epitope not being present on the [first] therapeutic agent, the [first] extra-cellular precipitate remaining in the extra-cellular fluid adjacent to the [first] bispecific reagent for [an extended period of time] at least several days.

70. (twice amended) A [first] therapeutic agent in accordance with claim 69 in which the [first] therapeutic agent is cell impermeant.

71. (amended) A [first] therapeutic agent in accordance with claim 69 in which a cell-impermeant chemical is attached to the [first] therapeutic agent, the cell-impermeant chemical causing the [first] therapeutic agent to be cell impermeant.

72. (twice amended) A [first] therapeutic agent in accordance with claim 71 in which the cell-impermeant chemical is selected from the group consisting of thiol, anionic materials, and materials [having] of a molecular weight greater than 1000 daltons.

73. (amended) A [first] therapeutic agent in accordance with claim 69

which is inherently soluble.

74. (amended) A [first] therapeutic agent in accordance with claim 69 in which the conversion of the [first] therapeutic agent comprises the conversion of the [first] therapeutic agent into a soluble intermediate molecule, the soluble intermediate molecule [being adapted to] including the characteristic to be [naturally] converted in the natural environment in the extra-cellular fluid into the [first] extra-cellular precipitate.

75. (twice amended) A [first] therapeutic agent in accordance with claim 74 in which the soluble intermediate molecule [is adapted to be naturally] having the characteristic to be oxidized in the natural environment with the extra-cellular fluid, the oxidized soluble intermediate molecule being [adapted to be] spontaneously dimerized, thereby forming the [first] extra-cellular precipitate.

76. (three times amended) A [first] therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds is selected from the group consisting of indoxyl-lactam[,] indoxyl-glycosides, [and the like] which when attached to position 3 of the indoxyl compounds are cleavable by the first enzyme moiety of the [first] bispecific reagent, the material remaining after cleaving at position 3 being a soluble reactive intermediate molecule which [is adapted to] can be oxidized and dimerized, thereby forming the [first] extra-cellular precipitate.

77. (amended) A [first] therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds [includes a substance which] can when attached to at least one of positions 4, 5, 6, and 7 of the indoxyl compound [alters

the characteristics] to alter the solubility, digestibility, color, and physical state of the indoxyl compounds and the [first] extra-cellular precipitate.

78. (amended) A [first] therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds includes phenyl compounds attached at position 5 of the indoxyl compound to alter the [characteristics] solubility, digestibility, color, and physical state of the indoxyl compounds and the [first] extra-cellular precipitate.

79. (amended) A [first] therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds includes benzyloxy compounds and derivatives of benzyloxy compounds attached at position 5 of the indoxyl compounds to alter the [characteristics] solubility, digestibility, color, and physical state of the indoxyl compounds of the [first] extra-cellular precipitate.

80. (amended) A [first] therapeutic agent in accordance with claim 69 in which each of the indoxyl compounds includes 5,5-bi-indoxyls attached at position 5 of the indoxyl compounds to alter the [characteristics] solubility, digestibility, color, and physical state of the indoxyl compounds and of the [first] extra-cellular precipitate.

81. (amended) A [first] therapeutic agent in accordance with claim 80 in which two indoxyl compounds are attached via a spacer molecule.

82. (amended) A [first] therapeutic agent in accordance with claim 69 which has a soluble moiety and an insoluble moiety, the soluble moiety [having] providing a solubilizing effect on the insoluble moiety and being cleaved by the